Insights from 4 Analysts on Lands' End
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2025
0mins
Should l Buy LE?
Source: Benzinga
Analyst Ratings Overview: In the past three months, four analysts have provided varied evaluations of Lands' End, with recent ratings showing a consistent bullish sentiment, maintaining an average price target of $20.00.
Financial Performance Challenges: Lands' End faces significant financial hurdles, including a revenue decline of approximately -7.28% over three months, a net margin of -1.25%, and below-average returns on equity and assets, indicating operational inefficiencies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LE
About LE
Lands' End, Inc. is a digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products and uniforms. The Company’s segments include U.S. eCommerce, Europe eCommerce, Outfitters, Third Party, Licensing and Retail. U.S. eCommerce segment offers products through the Company’s e-commerce Website. Europe eCommerce segment offers products primarily to consumers located in Europe and through e-commerce international websites and third-party affiliates. Outfitters segment sells uniform and logo apparel to businesses and their employees, as well as to student households through school relationships, located primarily in the United States. Third Party segment sells products direct to consumers through third-party marketplace Websites. Licensing segment earns royalties on the use of its trademark and any fulfillment fees for fulfillment services provided by the Company. Retail segment sells products through Company-operated stores located in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sarepta Therapeutics Reports Significant Three-Year Study Results
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
See More
U.S. Stocks Rise as Durable Goods Orders Surge
- Durable Goods Orders Surge: U.S. durable goods orders rose 5.3% month-over-month in November, exceeding market expectations of 3.7%, indicating strong economic recovery that could boost future consumption and investment.
- Market Performance: The Nasdaq Composite gained over 150 points, closing at 23,682.70, reflecting investor confidence in tech stocks and further driving overall market gains.
- Stock Highlights: Battalion Oil Corp's shares skyrocketed 235% to $4.29 after switching gas processing partners and boosting production, demonstrating the positive impact of strategic adjustments.
- Market Volatility: CN Energy Group Inc's shares fell 43% to $0.46 after receiving a Nasdaq delisting notice, highlighting the financial pressures and declining market confidence faced by the company.
See More
Significant Stock Movements for Multiple Companies
- Contract Cancellation Impact: Booz Allen Hamilton's stock fell over 5% after the Treasury Department canceled 31 contracts worth $4.8 million annually, highlighting the significant impact of government contracts on company finances.
- Investor Confidence Rebound: Investor Michael Burry's purchase of GameStop shares drove the stock up nearly 7%, indicating a market reassessment of the company's future value, even as Burry does not rely on a short squeeze for long-term gains.
- Rare Earth Mining Growth: USA Rare Earth shares surged 15% after the Trump administration took a stake, with plans to issue 16.1 million shares and 17.6 million warrants, demonstrating the positive influence of policy support on the rare earth sector.
- Biotech Breakthrough: Sarepta Therapeutics saw a 10% stock increase following its Elevidys study showing significant efficacy, with all Duchenne muscular dystrophy patients able to walk, underscoring the company's innovative potential in the biotech field.
See More
Lands' End Stock Rises Approximately 39% Following Joint Venture Agreement with WHP Global
Company Overview: Lands' End has announced a significant venture deal with WHP Global, which will see WHP acquire a 39% stake in the company.
Strategic Implications: This partnership is expected to enhance Lands' End's growth strategy and expand its market presence through WHP's expertise in brand management.
See More
Lands' End Forms Joint Venture with WHP Global, Shares Surge
- Joint Venture Agreement: Lands' End and brand management firm WHP Global have formed a joint venture that delivers $300 million in cash proceeds, enabling full repayment of approximately $234 million in term loans, thereby enhancing financial stability and shareholder value.
- Intellectual Property Contribution: Lands' End will contribute all its intellectual property and related assets, including all licensing agreements, while WHP Global will pay $300 million for a 50% controlling stake, ensuring strategic collaboration in brand expansion.
- Minimum Royalty Payments: The joint venture agreement includes guaranteed minimum royalty payments of $50 million per year, which will enhance future revenue potential as the brand expands, thereby improving the company's long-term profitability.
- Stock Buyback Plan: WHP Global plans to initiate a tender offer for up to $100 million of Lands' End shares at $45 per share, potentially acquiring up to 7% of outstanding shares, further boosting market confidence and enhancing shareholder returns.
See More
Lands' End to Participate in 28th Annual ICR Conference on January 12, 2025
- Conference Participation: Lands' End will participate in the 28th Annual ICR Conference on January 12, 2025, in Orlando, Florida, with CEO Andrew McLean and CFO Bernie McCracken attending, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The fireside chat will be webcast live, allowing investors to listen via the company’s website, with an online archive available for 90 days post-event, thereby enhancing interaction and transparency with investors.
- Brand Positioning: As a leading digital retailer, Lands' End offers a diverse range of apparel and home products, and participating in such industry events helps showcase its brand strength and market positioning, further solidifying its place in the apparel retail market.
- Strategic Communication: By engaging in direct dialogue with investors, Lands' End aims to convey its future development strategies and market opportunities, thereby boosting investor confidence and driving long-term growth for the company.
See More
Sarepta Therapeutics Reports Significant Three-Year Study Results
- Clinical Trial Results: Sarepta Therapeutics reported significant three-year results from the EMBARK study, showing that patients treated with Elevidys demonstrated statistically significant efficacy in motor function assessments, leading to a 9.8% stock price increase to $23.20, indicating enhanced competitiveness in Duchenne muscular dystrophy treatment.
- Positive Market Reaction: Following the release of favorable clinical data, there was a surge in demand for Sarepta's shares, reflecting investor optimism about the biopharmaceutical sector's outlook, which may attract more capital into the industry.
- Industry Impact: Sarepta's success could inspire other biopharmaceutical companies to increase investments in rare disease research and development, thereby fostering innovation and growth across the sector.
- Investor Confidence Boost: The success story of Sarepta may bolster investor confidence in biotech stocks, particularly as market conditions continue to favor increased focus on the healthcare sector.
See More
U.S. Stocks Rise as Durable Goods Orders Surge
- Durable Goods Orders Surge: U.S. durable goods orders rose 5.3% month-over-month in November, exceeding market expectations of 3.7%, indicating strong economic recovery that could boost future consumption and investment.
- Market Performance: The Nasdaq Composite gained over 150 points, closing at 23,682.70, reflecting investor confidence in tech stocks and further driving overall market gains.
- Stock Highlights: Battalion Oil Corp's shares skyrocketed 235% to $4.29 after switching gas processing partners and boosting production, demonstrating the positive impact of strategic adjustments.
- Market Volatility: CN Energy Group Inc's shares fell 43% to $0.46 after receiving a Nasdaq delisting notice, highlighting the financial pressures and declining market confidence faced by the company.
See More
Significant Stock Movements for Multiple Companies
- Contract Cancellation Impact: Booz Allen Hamilton's stock fell over 5% after the Treasury Department canceled 31 contracts worth $4.8 million annually, highlighting the significant impact of government contracts on company finances.
- Investor Confidence Rebound: Investor Michael Burry's purchase of GameStop shares drove the stock up nearly 7%, indicating a market reassessment of the company's future value, even as Burry does not rely on a short squeeze for long-term gains.
- Rare Earth Mining Growth: USA Rare Earth shares surged 15% after the Trump administration took a stake, with plans to issue 16.1 million shares and 17.6 million warrants, demonstrating the positive influence of policy support on the rare earth sector.
- Biotech Breakthrough: Sarepta Therapeutics saw a 10% stock increase following its Elevidys study showing significant efficacy, with all Duchenne muscular dystrophy patients able to walk, underscoring the company's innovative potential in the biotech field.
See More
Lands' End Stock Rises Approximately 39% Following Joint Venture Agreement with WHP Global
Company Overview: Lands' End has announced a significant venture deal with WHP Global, which will see WHP acquire a 39% stake in the company.
Strategic Implications: This partnership is expected to enhance Lands' End's growth strategy and expand its market presence through WHP's expertise in brand management.
See More
Lands' End Forms Joint Venture with WHP Global, Shares Surge
- Joint Venture Agreement: Lands' End and brand management firm WHP Global have formed a joint venture that delivers $300 million in cash proceeds, enabling full repayment of approximately $234 million in term loans, thereby enhancing financial stability and shareholder value.
- Intellectual Property Contribution: Lands' End will contribute all its intellectual property and related assets, including all licensing agreements, while WHP Global will pay $300 million for a 50% controlling stake, ensuring strategic collaboration in brand expansion.
- Minimum Royalty Payments: The joint venture agreement includes guaranteed minimum royalty payments of $50 million per year, which will enhance future revenue potential as the brand expands, thereby improving the company's long-term profitability.
- Stock Buyback Plan: WHP Global plans to initiate a tender offer for up to $100 million of Lands' End shares at $45 per share, potentially acquiring up to 7% of outstanding shares, further boosting market confidence and enhancing shareholder returns.
See More
Lands' End to Participate in 28th Annual ICR Conference on January 12, 2025
- Conference Participation: Lands' End will participate in the 28th Annual ICR Conference on January 12, 2025, in Orlando, Florida, with CEO Andrew McLean and CFO Bernie McCracken attending, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The fireside chat will be webcast live, allowing investors to listen via the company’s website, with an online archive available for 90 days post-event, thereby enhancing interaction and transparency with investors.
- Brand Positioning: As a leading digital retailer, Lands' End offers a diverse range of apparel and home products, and participating in such industry events helps showcase its brand strength and market positioning, further solidifying its place in the apparel retail market.
- Strategic Communication: By engaging in direct dialogue with investors, Lands' End aims to convey its future development strategies and market opportunities, thereby boosting investor confidence and driving long-term growth for the company.
See More
